I've read a lot recently about tumour profiling - matching a specific tumour to a specific drug. I am on a clinic trial at the moment called rucaparib as I have a BRCA1 gene mutation - grade 3b ovarian cancer.
The trial is under the auspices of Clovis Oncology Inc foundationmedicine.com/pdf/... in collaboration with Foundation Medicine. Foundation Medicine was recently approached by Bill Gates who decided to investment in the company. Foundation Medicine has developed a test that can match a tumour sample to a genetic mutation that could be targeted by a specific drug or clinical trial.
“Bill Gates, global-health philanthropist met with Michael Pellini, CEO of Foundation Medicine, to talk about Foundation's $5,800 test which "analyzes tissue biopsies for some 280 genetic mutations that are suspected of driving growth and proliferation of tumors. More than 700 oncologists have ordered the test, which was officially launched in June, in an effort to match patients with medicines that target the genetic anomalies specific to their tumors."
“In one recent case, Dr. Pellini says, a sample from a woman with advanced pancreatic cancer yielded a response for 'her2,' an alteration associated with a certain form of breast cancer. She was treated and her cancer responded to the breast-cancer drug Herceptin. Few oncologists would think to look for her2 in a patient with pancreatic cancer, he says.”
I went to see Justin Stebbings at The LOC in London theloc.com/ who uses a similiar company to profile his patients. He mentioned that Bupa has funded this so it may be worth checking out if you are covered by a private insurance company.
Further Chemosensitivity Testing, incl. Complementary Therapies.....
I have also researched a company in Greece that analyses cancer cells’ resistance or sensitivity to both conventional AND complementary agents as well. The test costs approximately £1,500. rgcc-uk.com/wp-content/them...